Bank of America (NYSE: BAC) raised their price target on shares of Auxilium Pharma (NASDAQ: AUXL) from $20.00 to $24.00 in a research note issued on Saturday.

Separately, analysts at RBC Capital (NYSE: RY) upgraded shares of Auxilium Pharma from a “sector perform” rating to an “outperform” rating in a research note to investors on Wednesday. They now have a $26.00 price target on the stock, up previously from $20.00. Analysts at Jefferies Group (NYSE: JEF) reiterated a “buy” rating on shares of Auxilium Pharma in a research note to investors on Friday, December 2nd. They now have a $24.00 price target on the stock. Also, analysts at Zacks Investment Research reiterated a “neutral” rating on shares of Auxilium Pharma in a research note to investors on Monday, November 21st. They now have a $18.00 price target on the stock.

Auxilium Pharmaceuticals, Inc. ( Auxilium) is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists. As of December 31, 2010, the Company markets two products in the United States: XIAFLEX and Testim. XIAFLEX is an injectable collagenase that the Company in-licensed from BioSpecifics. Under its agreement with BioSpecifics, it has exclusive worldwide rights to develop, market and sell certain products containing XIAFLEX, other than dermal formulations labeled for topical administration. As of December 31, 2010, its product pipeline includes XIAFLEX for the treatment of Peyronie’s disease (Peyronie’s), which is in phase III, and XIAFLEX for the treatment of Adhesive Capsulitis (Frozen Shoulder syndrome), which is in phase II.

Auxilium Pharma traded down 1.97% on Friday, hitting $19.90. Auxilium Pharma has a 52-week low of $13.59 and a 52-week high of $25.10. The stock has a 50-day moving average of $18.98 and a 200-day moving average of $17.15. The company’s market cap is $954.2 million.

Comments

Search RSS

All rights reserved."